Fig. 3From: Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristicsForest plots of HRs comparing A OS and B PFS between pembrolizumab-based therapy and chemotherapyBack to article page